Phase 4 Osteoporosis Trial, Recruiting NCT06767150 Sponsor: University Hospital, Toulouse Condition: Osteoporosis
Back to Osteoporosis

Phase 4 Osteoporosis Trial, Recruiting

NCT06767150
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a woman who has gone through menopause and has been diagnosed with osteoporosis (thinning of the bones)
  • You have been taking a medication called denosumab for at least 2 years, and your doctor has decided it is time to stop it because your treatment has gone well (no new broken bones, no new risk factors, and your bone density has not dropped significantly)
  • Before you started denosumab, you either had a serious fracture (broken bone) or your bone density scan showed significantly low bone density in your spine or hip

Who may not be able to join:

  • You were taking denosumab for a bone condition other than menopause-related osteoporosis
  • You have an endocrine (hormonal) disease that is not well controlled, or you have liver failure
  • You have taken certain medications that affect bone health in the past year, including bisphosphonates, teriparatide, romosozumab, certain hormone-related drugs, or steroid tablets at higher doses (confirm with trial site)
  • You have kidney disease that is moderately severe or worse, or you have previously had a bad reaction to a medication called zoledronic acid
  • You are not able to give your own consent to take part, or you are unable to complete study forms, or you are under legal protection (confirm with trial site)
  • You are unlikely to follow the study plan reliably, or you have issues with alcohol or drug dependency

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: 05 61 77 73 75

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
2 October 2025
Est. completion
1 October 2030

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Maintain lumbar bone mineral density (BMD) after 1 year of ZOL

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov